Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RVLP

RVL Pharmaceuticals (RVLP) Stock Price, News & Analysis

RVL Pharmaceuticals logo

About RVL Pharmaceuticals Stock (NASDAQ:RVLP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.00
$0.19
52-Week Range
N/A
Volume
63.96 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVLP Stock News Headlines

Raval ICS Ltd.
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
RVLPQ RVL Pharmaceuticals plc
RVL Pharmaceuticals PLC RVLPQ
See More Headlines

RVLP Stock Analysis - Frequently Asked Questions

RVL Pharmaceuticals plc (NASDAQ:RVLP) released its quarterly earnings results on Monday, March, 20th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.03. The firm had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that RVL Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Cardiff Oncology (CRDF), Osmotica Pharmaceuticals (OSMT), AbCellera Biologics (ABCL), Amarin (AMRN) and Coda Octopus Group (CODA).

Company Calendar

Last Earnings
3/20/2023
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RVLP
Fax
N/A
Employees
125
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$49.72 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
106,504,000
Optionable
Optionable
Beta
N/A
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:RVLP) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners